San Francisco Bay Area biotech stories.
Monday, July 23, 2012
Alzheimer's drug bapineuzumab fails late-stage trial
A closely watched Alzheimer's drug trial failed a late-stage test,
. The trial is the first of four with bapineuzumab by Pfizer partner Janssen Alzheimer Immunotherapy R&D LLC of South San Francisco. The trial of the intravenous drug focused on patients with mild-to-moderate Alzheimer's disease who carry a specific genotype called ApoE4.
Share to Twitter
Share to Facebook
Share to Pinterest
Janssen Alzheimers Immunotherapy
Post a Comment
Post Comments (Atom)